Register an account to search through 14,000+ stocks! 

Ad

ARNA – Arena Pharmaceuticals Inc

Ad

✔ COMPLIANT

★★★

Biotechnology & Medical Research | USA

Business: PASS

Arena Pharmaceuticals Inc has cleared the Business screen. Its business activity is compliant with the Shariah standard. If you find this result mistaken or questionable, let us know in the comments.

Financials: PASS

The financials pass all the three standards we check against.

FTSE

Debt/A3.83%
Cash/A18.44%
(AR+C)/A18.44%

AAOIFI

Debt/MC0.79%
Cash/MC15.24%

DJIM

Debt/24MC1.17%
Cash/24MC5.65%
AR/24MC%

Total Analysts: 14

Recommendation Rating

2.8

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 97.7

Low: 14

High: 105

Market cap5802418499
Assets1190720000
Dividends per Share
Revenue Growth-100

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. The Company’s clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five. Olorinab, an orally available, potent, peripherally acting, selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate. APD418 is an adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the adverse events associated with available inotropes. Temanogrel is a peripherally acting and selective 5HT2a inverse agonist designed to inhibit serotonin (5-HT) mediated amplification of platelet aggregation and vasoconstriction.

✔ FTSE✔ AAOIFI✔ DJIM

✔ COMPLIANT

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.

Ad

Responses